A pilot study of preoperative and postoperative chemotherapy in patients with operable gastric cancer: Australasian Gastrointestinal Trials Group study 9601

ANZ Journal of Surgery

Volumn 77, Issue 4, 2007, Pages 247-252

  Findlay, Michael ^a,c   Storey, David ^b   Gebski, Val ^c   Hargreaves, Carol ^c   Cullingford, Graham ^f   Boyer, Michael ^b   Trotter, James ^g   Archer, Stephen ^g   Davidson, Andrew ^f   Johnston, Peter ^a   Yuen, Jennifer ^c   Dhillon, Haryana ^c   Della Fiorentina, Stephen ^d   Richardson, Gary ^h   Truskett, Philip ^e   Goldstein, David ^e  

^a WELLINGTON HOSPITAL   (New Zealand)

^b ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d LIVERPOOL HOSPITAL   (Australia)

^e PRINCE OF WALES HOSPITAL   (Australia)

^f FREMANTLE HOSPITAL   (Australia)

^g ROYAL PERTH HOSPITAL   (Australia)

^h CABRINI HOSPITAL   (Australia)

Author keywords

Adjuvant chemotherapy; ECF; Gastric cancer; Neoadjuvant chemotherapy; Surgery

Indexed keywords

CISPLATIN; EPIRUBICIN; FLUOROURACIL;

ADENOCARCINOMA; ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CHEMOTHERAPY; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTINUOUS INFUSION; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ENDOSCOPY; FEMALE; HEART INFARCTION; HUMAN; INFECTION; LAPAROSCOPY; LIVER METASTASIS; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; NAUSEA AND VOMITING; NEUTROPENIA; PILOT STUDY; POSTOPERATIVE CARE; PREOPERATIVE TREATMENT; SEPSIS; STOMACH CANCER; SUDDEN DEATH; SURVIVAL TIME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AUSTRALIA; CHEMOTHERAPY, ADJUVANT; CISPLATIN; COMBINED MODALITY THERAPY; EPIRUBICIN; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PILOT PROJECTS; STOMACH NEOPLASMS; TREATMENT OUTCOME;

EID: 33947185334     PISSN: 14451433     EISSN: 14452197     Source Type: Journal    
DOI: 10.1111/j.1445-2197.2007.04027.x     Document Type: Article

References (21)

1. Sullivan R, Findlay M, Zalcberg J. Adjuvant therapy for gastric cancer; an evidence based review. Am. J. Cancer. 2006; 5: 111-21.
2. Allum WH, Powell DJ, McConkey CC et al. Gastric cancer: a 25-year review. Br. J. Surg. 1989; 76: 535-40.
3. Parkin DM, Pisani P, Ferlay J. Global cancer statistics. CA Cancer J. Clin. 1999; 49: 33-64.
4. Carmalt HL, Gillett DJ, Hollinshead JW. Carcinoma of the stomach: a review with special reference to total gastrectomy. Aust. N. Z. J. Surg. 1990; 60: 759-63.
5. Blot WJ, Devesa SS, Kneller RW, Fraumeni JF Jr. Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA 1991; 265: 1287-9.
6. Kajitani T.; Japanese Research Society for the Study of Gastric Cancer. The general rules for gastric cancer study in Surgery and Pathology. Jpn. J. Surg. 1981; 11: 127-45.
7. Bonenkamp JJ, Hermans J, Sasako M et al. Extended lymph-node dissection for gastric cancer. N. Engl. J. Med. 1999; 340: 908-14.
8. Cuschieri A, Fayers P, Fielding J et al. Postoperative morbidity and mortality after D1 and D2 resections for gastric cancer: preliminary results of the MRC randomised controlled surgical trial. The Surgical Cooperative Group. Lancet 1996; 347: 995-9.
9. Panzini I, Gianni L, Fattori PP et al. Adjuvant chemotherapy in gastric cancer: a meta-analysis of randomized trials and a comparison with previous meta-analyses. Tumori 2002; 88: 21-7.
10. Macdonald JS, Smalley SR, Benedetti J et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N. Engl. J. Med. 2001; 345: 725-30.
11. Findlay M, Cunningham D, Norman A et al. A phase II study in advanced gastro-esophageal cancer using epirubicin and cisplatin in combination with continuous infusion 5-fluorouracil (ECF). Ann. Oncol. 1994; 5: 609-16.
12. Webb A, Cunningham D, Scarffe J et al. A randomized trial comparing ECF with FAMTX in advanced esophago-gastric cancer (Abstract # 1462). In: Perry MC (ed.). Proceedings of American Society of Clinical Oncology; Philadelphia: American Society of Clinical Oncology, 1996. 18 May 1996; 465.
13. Ross P, Nicolson M, Cunningham D et al. Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) with epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. J. Clin. Oncol. 2002; 20: 1996-2004.
14. Fink U, Stein HJ, Schuhmacher C, Wilke HJ. Neoadjuvant chemotherapy for gastric cancer: update. World J. Surg. 1995; 19: 509-16.
15. Cox K, Visintin L, Kovac S et al. Establishing a programme for continuous ambulatory infusion chemotherapy. Aust. N. Z. J. Med. 1997; 27: 680-84.
16. Bern MM, Lokich JJ, Wallach SR et al. Very low doses of warfarin can prevent thrombosis in central venous catheters. A randomized prospective trial. Ann. Intern. Med. 1990; 112: 423-8.
17. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47: 207-14.
18. Mehta CR, Cain KC. Charts for the early stopping of pilot studies. J. Clin. Oncol. 1984; 2: 676-82.
19. Webb A, Cunningham D, Scarffe JH et al. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J. Clin. Oncol. 1997; 15: 261-7.
20. Cunningham D, Allum WH, Stenning SP et al. Perioperative chemotherapy versus surgery alone for respectable gastroesophageal cancer. N. Engl. J. Med. 2006; 355: 11-20.
21. Macdonald JS, Schnall SF. Adjuvant treatment of gastric cancer. World J. Surg. 1995; 19: 221-5.